Restarting Wegovy After a Six-Month Break: What Happens Next

Do you go back to the beginning of the dose ladder?

This is the question our prescribers hear most weeks from people returning to Wegovy after a significant gap. The short answer, at six months, is almost certainly yes. Semaglutide's GI effects (nausea, bloating, changes to bowel habit) are dose-dependent and tolerance built during your first course does not reliably persist after that length of time away. Jumping straight back to 1.7 mg or 2.4 mg when your gut has essentially reset carries a real risk of severe nausea or vomiting that makes continuing difficult.

The licensed titration pathway, described in full on the Wegovy treatment page, starts at 0.25 mg for four weeks, then steps up at roughly monthly intervals through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg (or 7.2 mg, with the newer single-dose pen, for those going to the higher maintenance). Retracing those steps feels slow, but it is considerably less disruptive than a restart that has to be abandoned in week two because of GI distress. Your prescriber may, in some circumstances, allow a slightly compressed schedule if you tolerated previous doses well and stopped for reasons unrelated to side effects, that flexibility is exactly why this needs a clinical conversation rather than a self-directed plan.

The NHS guidance on weight-management injections reinforces the principle that titration decisions sit with the supervising clinician at every stage of treatment, including re-initiation.

What typically happens to weight during a six-month break?

Semaglutide does not leave behind a lasting metabolic change once it clears your system. The biological drivers of appetite that the medicine was suppressing reassert themselves. Data from the STEP 1 extension, as covered in the original STEP 1 trial publication in the New England Journal of Medicine, showed that participants who stopped semaglutide regained a substantial proportion of lost weight within a year, roughly two-thirds of the weight that had been lost returned over 52 weeks post-treatment. Six months into that window, meaningful regain is common, though highly individual.

This is not a sign of failure. Obesity is a chronic condition, and the medicine addresses it while it is being taken, much like blood pressure medication keeps readings controlled only during use. Understanding that dynamic tends to change how people frame a restart: not as correcting a relapse but as resuming ongoing management. If you're unsure how to think about the longer arc of treatment, the weight-loss treatments overview covers what supervised programmes typically look like over time.

From a practical standpoint, weight regain over six months may also affect your current eligibility picture. A prescriber will look at where your BMI and weight-related health markers sit now, not where they were when you first started, which is another reason clinical reassessment before restart matters.

Why you stopped shapes how you restart

Stopping Wegovy is rarely a single-reason story. Supply disruption, cost, side effects that felt unmanageable, a period of pregnancy or planned conception, or simply feeling you'd reached a stable point, each of these leads to a somewhat different restart conversation. If you stopped because of persistent nausea or reflux at a particular dose, returning to that dose level will require the same careful approach (or an adjusted one). If you stopped because of access or affordability, you and your prescriber may want to plan a more consistent supply route before you begin again.

Cost is a real and legitimate part of that planning. Private treatment pricing varies by dose and provider; the context around Wegovy pricing in the UK is worth reading if that was part of why you paused. For people who stopped due to interactions worries (say, questions about their antidepressant) a page like the one covering Wegovy alongside sertraline gives a starting point, though the prescriber review remains the definitive step.

If your break was shorter than six months, the restart picture shifts. A two-month gap often means less tolerance reset, and your prescriber may take a different view on where to re-enter the schedule, while our guide to restarting Wegovy after four months covers the middle ground between a short pause and a longer absence. The principle holds across all restart timeframes: the gap length, the reason for stopping, and your current health status together determine the plan.

Getting a prescription to restart

Wegovy is a prescription-only medicine. You cannot simply order more pens once your previous supply runs out, a new clinical assessment is required before any repeat supply, even if you were previously stable on a maintenance dose. That assessment exists to check that nothing has changed in your health since you last took it: new medications, changes to relevant conditions, weight shifts that affect the clinical picture.

At nume, every repeat order, including restarts after a break of any length, is reviewed personally by a GPhC-registered prescriber on our clinical team, a real clinician reads your answers, not an automated system. If you're ready to start that process, you can check your eligibility and begin a free consultation. Our prescribers will consider your specific situation, including how long you've been off treatment and what prompted the break, before making any prescribing decision.